Invicta Medical

Invicta Medical operates in the obstructive sleep-apnea device market, where established approaches include CPAP, oral appliances, and implanted nerve-stimulation systems such as Inspire. Its stated differentiation is an emphasis on neurostimulation therapies intended to address practical limitations of existing options, including intrusiveness, cost, and patient adherence. The company’s product record identifies an OSA Therapy, while its patent activity indicates work on implantable electrodes, signal-delivery devices, remote power delivery, and positioning methods. That technical focus places Invicta closer to implantable neuromodulation companies than to software-only sleep monitoring businesses. The company has raised $53.6 million across five recorded rounds, including a $20.999998 million Series B in 2018 and a $24.977627 million Series A in 2022. Relative to alternatives such as CPAP and Inspire, Invicta’s potential advantage is a different electrode-placement and stimulation approach; its principal market risks remain clinical validation, procedural adoption, reimbursement, and competition from established therapies.

Invicta Medical’s growth trajectory shows a transition from early formation to substantial device-development financing. Founded in 2013, the company recorded a $1 million Seed round in 2015, a $6.6 million Series A in 2016, and a $20.999998 million Series B in 2018. A further $24.977627 million Series A was recorded on Oct 14, 2022, followed by non-equity assistance from MedTech Innovator on May 29, 2024. Cumulative funding is listed at $53.577625 million across five rounds, with seven investors. Its employee range is listed as 11 to 50, and the current team includes dedicated clinical and regulatory, engineering, business, and executive roles. Patent activity from 2023 and 2024 marks an important technical-development phase, particularly around implantable electrodes, remote power delivery, and signal-placement techniques for sleep apnea.